brodalumab

Trials studying brodalumab

• phase1Brodalumab in the Treatment of Immune-Related Adverse Eventsrecruitingn=11
• phase4Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weightcompletedn=385
• —Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivityactive not recruitingn=394
• phase4An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjectsactive not recruitingn=2
• —LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasisenrolling by invitationn=3,500
• phase3Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasisterminatedn=12
• phase4Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumabterminatedn=113
• phase4A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasiscompletedn=210